Axe Compute Inc. Q1 FY2024 earnings call

• Completed a retrospective multiyear study with UPMC Magee-Womens Hospital on ovarian cancer, achieving strong predictive models with high accuracy, and the study's abstract was accepted for presentation at ASCO.
• Collaborated with Fujifilm to co-market EndoPrep sample treatment technology and PYROSTAR bacterial endotoxin detection reagent.
• Made progress with FluGen on a first-of-its-kind intranasal flu vaccine under a $6.2 million Phase IIb grant from the US Department of Defense.
• Developed a novel protein expression method for G protein-coupled receptors and other membrane protein classes, supporting drug discovery.
• Provided updates on collaborations with Cvergenx, working on genomics-based precision radiation therapy and drug discovery using AI.

In the first quarter of 2024, Predictive Oncology recorded revenues of $420,000. The Eagan operating segment was the primary contributor, generating $404,000 in revenues for the quarter ended March 31, 2024, which accounts for approximately 96.19% of the total revenue. In the comparable period of 2023, revenues were $240,000, with the Eagan segment contributing $216,000, making up 90% of that total.

Q: A: Q: A: